Nivolumab Plus Relatlimab Shows Sustained PFS Benefit in Advanced Melanoma
Source: Oncology News Central, February 2025
Nivolumab (Opdivo) plus relatlimab (Opdualag) significantly improves progression-free survival (PFS) in advanced melanoma compared with anti–PD-1 monotherapy alone, according to three-year descriptive results of the RELATIVITY-047 trial that confirm the combination’s sustained benefit.
Researchers led by Hussein A. Tawbi, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston, also noted that this analysis was the first to show an overall survival (OS) hazard ratio (HR) with a 95% confidence interval (CI) upper bound of less than 1.
“The 3-year follow-up data show a statistically significant PFS and clinically meaningful OS, showing that responses to this combination are quite durable,” said Ramya Muddasani, DO, MS, of City of Hope in Duarte, California, who was not involved in the study. “This will help clinicians build confidence in utilizing this regimen in the front-line setting.”